Literature DB >> 11301186

Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells.

H Tayebi1, F Kuttler, P Saas, A Lienard, B Petracca, V Lapierre, C Ferrand, T Fest, J Cahn, D Blaise, M Kuentz, P Hervé, P Tiberghien, E Robinet.   

Abstract

Some phenotypic and functional properties of lymphocytes from bone marrow or peripheral blood stem cell donors were compared in a randomized study. Lymphocyte subsets were analyzed by immunocytometry in blood harvested from bone marrow donors (n = 27) and from peripheral blood stem cell donors before and after granulocyte colony-stimulating factor mobilization (n = 23) and in bone marrow and peripheral blood stem cell grafts. Granulocyte colony-stimulating factor mobilization increased the blood T and B, but not NK, lymphocyte counts. All lymphocyte counts were approximately 10-fold higher in peripheral blood stem cell grafts than in bone marrow grafts. Analysis of CD25, CD95, HLA-DR, and CD45RA expression shows that T-cell activation level was lower after granulocyte colony-stimulating factor mobilization. Similarly, granulocyte colony-stimulating factor reduced by twofold to threefold the percentage of interferon-gamma, interleukin-2, and tumor necrosis factor-alpha-secreting cells within the NK, NK-T, and T-cell subsets and severely impaired the potential for interferon-gamma production at the single-cell level. mRNA levels of both type 1 (interferon-gamma, interleukin-2) and type 2 (interleukin-4, interleukin-13) cytokines were approximately 10-fold lower in peripheral blood stem cell grafts than in bone marrow grafts. This reduced potential of cytokine production was not associated with a preferential mobilization of so-called "suppressive" cells (CD3+CD4-CD8-, CD3+CD8+CD56+, or CD3+TCRVA24+CD161+), nor with a modulation of killer cell receptors CD161, NKB1, and CD94 expression by NK, NK-T, or T cells. Our data demonstrate in a randomized setting that quantitative as well as qualitative differences exist between a bone marrow and a peripheral blood stem cell graft, whose ability to produce type 1 and type 2 cytokines is impaired.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11301186     DOI: 10.1016/s0301-472x(01)00613-0

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  18 in total

Review 1.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation.

Authors:  Raphael Itzykson; Marie Robin; Helene Moins-Teisserenc; Marc Delord; Marc Busson; Aliénor Xhaard; Flore Sicre de Fontebrune; Régis Peffault de Latour; Antoine Toubert; Gérard Socié
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

3.  Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort.

Authors:  Z Gul; E Van Meter; M Abidi; I Ditah; M Abdul-Hussein; A Deol; L Ayash; L G Lum; E K Waller; V Ratanatharathorn; J Uberti; Z Al-Kadhimi
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

4.  Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation.

Authors:  Virginia Fisher; Hanh Khuu; Virginia David-Ocampo; Karen Byrne; Steven Pavletic; Michael Bishop; Daniel H Fowler; A John Barrett; David F Stroncek
Journal:  Transfusion       Date:  2013-10-10       Impact factor: 3.157

5.  Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.

Authors:  A Rosko; C Hofmeister; D Benson; Y Efebera; Y Huang; J Gillahan; J C Byrd; C E Burd
Journal:  Bone Marrow Transplant       Date:  2015-06-29       Impact factor: 5.483

Review 6.  Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors.

Authors:  Sara Mariucci; Bianca Rovati; Mariangela Manzoni; Matteo Giovanni Della Porta; Giuditta Comolli; Sara Delfanti; Marco Danova
Journal:  Clin Exp Med       Date:  2010-12-16       Impact factor: 3.984

7.  Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect.

Authors:  Song-He Chen; Xin Li; Xiao-Jun Huang
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

8.  Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells.

Authors:  P J Mannon; F Leon; I J Fuss; B A Walter; M Begnami; M Quezado; Z Yang; C Yi; C Groden; J Friend; R L Hornung; M Brown; S Gurprasad; B Kelsall; W Strober
Journal:  Clin Exp Immunol       Date:  2008-12-15       Impact factor: 4.330

Review 9.  Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden?

Authors:  J J Auletta; S M Devine; E K Waller
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

10.  Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.

Authors:  Yu Xiong; Manon Mouginot; Loic Reppel; Chongsheng Qian; Jean-Francois Stoltz; Danièle Bensoussan; Véronique Decot
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.